Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation

Webinar to be held Tuesday, December 2nd, at 8:00 am ETREDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper or the Company), a clinical stage ...

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 ...
Investor's Business Daily on MSN

Denali Therapeutics Shows Rising Price Performance With Jump To 83 RS Rating

On Monday, Denali TherapeuticsDNLI hit an important technical milestone, with its Relative Strength (RS) Rating climbing into ...
The American Journal of Managed Care

Balancing Clinical and Economic Considerations in Treatment Adoption

Panelists discuss how integrating clinical efficacy with cost-effectiveness ensures sustainable adoption of MASH therapies. Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights ...
Medscape

Expanding the Role of Immunotherapy in Early-Stage HR+ and Triple-Negative Breast Cancer

Dr Hope Rugo explores how new data suggest immunotherapy could reshape the standard of care for early-stage HR+ and ...
Clinical Pain Advisor

Predictive Modeling of Pain Modulation Mechanisms Using Accessible Clinical Measures

Researchers developed predictive models using routine clinical metrics to estimate pain modulation profiles in chronic pain.
Rheumatology Advisor

Tirzepatide Linked to Meaningful Reductions in SUA Levels in Adults With Obesity

Once-weekly tirzepatide is associated with clinically relevant reductions in SUA levels over 72 weeks, largely driven by substantial weight loss.